ScreenerHero

MTVA MetaVia Inc.

NAS · US · Healthcare · Biotechnology · metaviatx.com
1.460USD-1.35%Mkt Cap: 9.62M $P/E: —

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with devel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap9.62M USD
Enterprise Value-2.71M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.97M USD
Revenue/Share—
Last Price1.460 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.18
EV/Revenue—
P/S—
P/B1.43
EPS (TTM)-3.65
EPS (Forward)—
52W Range
0.96604% of range14.85
52W High14.85 USD
52W Low0.9660 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-243.26%
ROA-116.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.70M USD
CapEx (TTM)2.00K USD
FCF Margin—
FCF Yield-115.26%
Net Debt-12.46M USD
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.04
Current Ratio2.06
Quick Ratio1.99
Book Value/Sh1.04 USD
Cash/Share1.92 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 31, 2019
Splits
Last Split1:11
Split DateDec 5, 2025
Analyst Consensus
Rating—
Target (Mean)19.33 USD
Upside (mean)+1224.2%
Target Range8.000 USD – 30.00 USD
8.000+1224.2% to mean30.00
# Analysts3
Ownership
Shares Out.6.59M
Float4.80M
Insiders28.61%
Institutions13.87%
Short Interest
Short Ratio1.9d
Short % Float3.81%
Short % Out.2.78%
Shares Short183.47K
Short (prev mo.)211.34K
Technical
SMA 501.578 (-7.5%)
SMA 2002.364 (-38.2%)
Beta0.96
S&P 52W Chg16.45%
Avg Vol (30d)78.09K
Avg Vol (10d)54.85K
Technical Indicators
RSI (14)36.2
MACD-0.0318
MACD Signal-0.0069
MACD Hist.-0.0249
BB Upper1.792 USD
BB Middle1.625 USD
BB Lower1.459 USD
BB Width20.46%
ATR (14)0.0966 USD
Vol Ratio (20d)0.34x